Highlights From the IASLC Virtual Presidential Symposium

<p><span data-sheets-value= "{"1":2,"2":"<p>This week on <em>The ASCO Post Podcast</em>, we'll first hear about a study of the monoclonal antibody sintilimab in combination with pemetrexed and platinum to treat advanced nonsquamous non–small cell lung cancer. Then we'll review the results of the CheckMate 743 trial, which suggest a new standard of care in first-line treatment of unresectable malignant pleural mesothelioma.<br></p>"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week on The ASCO Post Podcast, we'll first hear about a study of the monoclonal antibody sintilimab in combination with pemetrexed and platinum to treat advanced nonsquamous non–small cell lung cancer. Then we'll review the results of the CheckMate 743 trial, which suggest a new standard of care in first-line treatment of unresectable malignant pleural mesothelioma.</span></p>